Tuberculosis

CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine

Retrieved on:

Freitag, April 26, 2024

Tao, Vaccination, Public, Pneumonia, DPT, Conference, Vaccine, CanSino Biologics, Shingles, ACFM, Meningitis, CSO, Streptococcus pneumoniae, CPMA, Tuberculosis, Attenuated vaccine, Ageing

Dr. Tao Zhu, Chief Scientific Officer (CSO) of CanSino Biologics Inc. (CanSinoBIO), was invited to give a presentation at the conference.

Key Points:

Dr. Tao Zhu, Chief Scientific Officer (CSO) of CanSino Biologics Inc. (CanSinoBIO), was invited to give a presentation at the conference.
Dr. Zhu introduced the latest progress and breakthrough made in the development of pneumococcal vaccines both in China and abroad, focusing on sharing the latest results from the clinical trials of the company's globally innovative protein-based pneumococcal vaccine (PBPV).
Positive results have been obtained from Phase I clinical trials of the PBPV.
The company is committed to developing pneumococcal vaccines, especially higher-valency serotype vaccines to improve the effectiveness of vaccines.

Mobile Health Celebrates 40 Years of Revolutionizing Occupational Health

Retrieved on:

Donnerstag, Mai 9, 2024

Education, Patient portal, PPD, Client portal, Portal, Transport, Vaccine, History, Documentation, MHealth, Workforce, Student, Government, Tuberculosis, COVID-19, OSHA, Nursing

NEW YORK, May 9, 2024 /PRNewswire/ -- Celebrating its 40th anniversary, Mobile Health, a leader in occupational health services, reflects on its journey from pioneering mobile services to a national authority. They emphasize innovation, client satisfaction, and adaptability, while embracing change and leveraging technology to streamline processes and meet evolving client needs.

Key Points:

NEW YORK, May 9, 2024 /PRNewswire/ -- Celebrating its 40th anniversary, Mobile Health, a leader in occupational health services, reflects on its journey from pioneering mobile services to a national authority.
As we look ahead, we're energized by the opportunities to continue pushing boundaries and shaping the future of occupational health."
Founded in 1984 by Bert Brodsky, the company's original vision was to provide occupational health services for home healthcare agencies through mobile units (vans).
With a keen eye on regulatory changes and industry trends, the company is poised to continue revolutionizing occupational health for years to come.

BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million

Retrieved on:

Dienstag, Mai 7, 2024

The compound represents a totally new concept of overcoming resistance and significantly potentiating the activity of an existing antibiotic, ethionamide (Eto).

Key Points:

The compound represents a totally new concept of overcoming resistance and significantly potentiating the activity of an existing antibiotic, ethionamide (Eto).
As part of the expanded collaboration, GSK will take an equity stake in BioVersys' latest investment round.
Adding to further investments from existing and new investors, this extends the Series C financing by CHF 12.3 million, resulting in total proceeds of CHF 44.9 million for the Series C round to date.
Dr. Marc Gitzinger, Chief Executive Officer and founder of BioVersys: "We are very pleased to announce both the expansion of our highly successful strategic collaboration with GSK and our partner’s participation in our latest financing round.

DocGo Announces Strong First Quarter 2024 Results

Retrieved on:

Mittwoch, Mai 8, 2024

DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced financial and operating results for the quarter ended March 31, 2024.

Key Points:

DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced financial and operating results for the quarter ended March 31, 2024.
Total revenue for the first quarter of 2024 was $192.1 million, compared to $113.0 million in the first quarter of 2023, an increase of 70%.
Transportation Services revenue in the first quarter of 2024 was $48.2 million, compared to $40.1 million for the first quarter of 2023, an increase of 20%.
Adjusted EBITDA1 was $24.1 million for the first quarter of 2024, compared to $5.6 million for the first quarter of 2023, an increase of 330%.

Novo Nordisk Foundation, Wellcome, and the Gates Foundation Join Forces to Accelerate Global Health Equity and Impact

Retrieved on:

Montag, Mai 6, 2024

HELSINGØR, Denmark, May 6, 2024 /PRNewswire/ -- The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation announced a new partnership to support critical scientific research and development (R&D) for global health. The partnership is focused on supporting science and innovation to advance solutions that are accessible and affordable to people in low- and middle-income countries (LMICs).

Key Points:

The three-year initiative was announced at the Novo Nordisk Foundation's Global Science Summit in Denmark, where each organization committed US$100 million, for a total of US$300 million.
"By pooling the vast experience and unique expertise of each organization—across research, technology, innovation, and enterprise—we can make advances that wouldn't otherwise be possible," said Mads Krogsgaard Thomsen, CEO, Novo Nordisk Foundation.
To better protect people globally from the devastating effects of climate change on health, solutions that draw across climate, health, and agricultural science will be needed.
By partnering with the Novo Nordisk Foundation and the Gates Foundation, we can raise ambition, and combine resources and networks to find new ways to advance global health research—especially for those with greatest need."

Novo Nordisk Foundation, Wellcome, and the Gates Foundation Join Forces to Accelerate Global Health Equity and Impact

Retrieved on:

Montag, Mai 6, 2024

HELSINGØR, Denmark, May 6, 2024 /PRNewswire/ -- The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation announced a new partnership to support critical scientific research and development (R&D) for global health. The partnership is focused on supporting science and innovation to advance solutions that are accessible and affordable to people in low- and middle-income countries (LMICs).

Key Points:

The three-year initiative was announced at the Novo Nordisk Foundation's Global Science Summit in Denmark, where each organization committed US$100 million, for a total of US$300 million.
"By pooling the vast experience and unique expertise of each organization—across research, technology, innovation, and enterprise—we can make advances that wouldn't otherwise be possible," said Mads Krogsgaard Thomsen, CEO, Novo Nordisk Foundation.
To better protect people globally from the devastating effects of climate change on health, solutions that draw across climate, health, and agricultural science will be needed.
By partnering with the Novo Nordisk Foundation and the Gates Foundation, we can raise ambition, and combine resources and networks to find new ways to advance global health research—especially for those with greatest need."

Detect-ION announces new funding to revolutionize health diagnostics in low-income regions

Retrieved on:

Mittwoch, Mai 1, 2024

VOC, Multimedia, Volatile organic compound, Organic compound, TB, Tuberculosis, Bill, Optimism, Melinda French Gates, Health, Congo, Hope, Democratic republic, Malaria, Medical imaging

This visionary project will leverage Detect-ION's chip-scale mass spectrometry for point-of-care breath diagnostics in LMICs, with an initial focus on detecting malaria and tuberculosis (TB) in human subjects across central Africa.

Key Points:

This visionary project will leverage Detect-ION's chip-scale mass spectrometry for point-of-care breath diagnostics in LMICs, with an initial focus on detecting malaria and tuberculosis (TB) in human subjects across central Africa.
Through the utilization of advanced mass spectrometry techniques, the project seeks to provide affordable and timely health diagnostics, potentially saving hundreds of thousands of lives annually.
The project's ultimate goal is to bridge the gap in healthcare disparities and provide vital health solutions to disadvantaged communities.
During this 16-month project, Detect-ION will pioneer the advancement of the diagnostic capabilities of miniaturized mass spectrometry, with human trials of this groundbreaking tool being conducted in the Democratic Republic of Congo.

Scientific leaders gather at global summit in Denmark to advance knowledge and solutions on health and sustainability

Retrieved on:

Dienstag, April 30, 2024

The goal is to explore the interaction between the world's biggest health and sustainability challenges and pave the way for new scientific breakthroughs.

Key Points:

The goal is to explore the interaction between the world's biggest health and sustainability challenges and pave the way for new scientific breakthroughs.
The summit is taking place on 6-7 May 2024 in Helsingør and focuses on the growing global burden of non-communicable diseases, infectious diseases, and climate change, and the interplay between them.
"At the Novo Nordisk Foundation, we work to improve the health of people and the planet," says Mads Krogsgaard Thomsen, CEO of the Foundation.
"These are closely connected but, all too often, scientific research occurs in silos and the outcomes don't meet the needs of a world facing complex challenges.

Scientific leaders gather at global summit in Denmark to advance knowledge and solutions on health and sustainability

Retrieved on:

Dienstag, April 30, 2024

The goal is to explore the interaction between the world's biggest health and sustainability challenges and pave the way for new scientific breakthroughs.

Key Points:

The goal is to explore the interaction between the world's biggest health and sustainability challenges and pave the way for new scientific breakthroughs.
The summit is taking place on 6-7 May 2024 in Helsingør and focuses on the growing global burden of non-communicable diseases, infectious diseases, and climate change, and the interplay between them.
"At the Novo Nordisk Foundation, we work to improve the health of people and the planet," says Mads Krogsgaard Thomsen, CEO of the Foundation.
"These are closely connected but, all too often, scientific research occurs in silos and the outcomes don't meet the needs of a world facing complex challenges.

5 Ways Heart Health Care Can Improve

Retrieved on:

Montag, April 29, 2024

"Finding that most people do not know the significant impact of heart disease is discouraging and even a bit frightening."

Key Points:

"Finding that most people do not know the significant impact of heart disease is discouraging and even a bit frightening."
Non-traditional approaches to health care are needed to address the social and structural determinants of health by moving evidence-based approaches rapidly into communities to address food insecurity, transportation problems, education, housing, access to care, chronic psychosocial stress and other social needs.
The interconnectedness of organ systems, mechanisms of disease and stages of life are critical to understanding the role cardiovascular health plays in overall health.
As we apply these same clinical and epidemiological methods to the someday hopeful eradication of heart disease and stroke, the American Heart Association is making great progress.